CEO Shaun Bagai to discuss the momentum of RenovoRx’s commercialization efforts for its RenovoCath ® device, including an update on initial revenues generated, and continued progress on the ongoing Phase III TIGeR-PaC clinical trial MOUNTAIN VIEW, Calif. / Apr 04, 2025 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and... Read More

Revenues from RenovoCath Expected to Grow Sequentially During 2025 with Expansion of New Customer Purchase Orders and Customer Reorders Completion of TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Reports 2024 Financial Results Including $7.2 Million Cash Position as of December 31, 2024, with Additional $12.1 Million in Gross Proceeds Raised in... Read More

Data supports the novel Trans-Arterial Micro-Perfusion (TAMP TM ) therapy platform for targeted chemotherapy delivery for the potential to minimize a therapy’s toxicities versus systemic intravenous therapies Data shows localized, intra-arterial delivery of gemcitabine with FDA-cleared RenovoCath® device (known as IAG) resulted in lower systemic levels of drug compared to intravenous delivery of gemcitabine MOUNTAIN VIEW,... Read More

Peer-reviewed paper will be honored as a Journal of Vascular and Interventional Radiology Award-Winning Paper Pre-clinical data show that TAMP increases intra-arterial pressure, improving drug delivery with 100-fold increase in local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of existing and new treatments MOUNTAIN VIEW, Calif. / Mar 26,... Read More

Shaun Bagai to discuss the momentum of RenovoRx’s commercialization efforts for its RenovoCath ® device, including an update on initial revenues generated, and continued progress on the ongoing Phase III TIGeR-PaC clinical trial MOUNTAIN VIEW, Calif. / Mar 20, 2025 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and... Read More

New human pharmacokinetic (PK) and other pre-clinical data supports use of RenovoRx’s novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform MOUNTAIN VIEW, Calif. / Mar 19, 2025 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared drug-delivery device, is proud... Read More

Initial Revenues Expected this Quarter, and Customer Pipeline for RenovoCath Standalone Device Continues to Expand, Including High Volume National Cancer Institute-Designated Centers RenovoCath Gaining Validation in an Initial U.S. Market Estimated at $400 Million Annually MOUNTAIN VIEW, Calif. / Feb 26, 2025 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing... Read More

Pre-Clinical Data Recently Presented at the SIO 2025 Annual Conference Show that Intra-Arterial Administration of a Drug with the RenovoCath ® Delivery System via TAMP May Improve Delivery in Difficult-to-Treat Cancers The Results of this Pre-clinical Study Support a More Optimized Drug Delivery Method in Tumors that Lack Sufficient Blood Supply for Adequate Drug Penetration During Therapy MOUNTAIN VIEW, Calif. / Feb 13,... Read More

Financing led by new fundamental healthcare institutional investors MOUNTAIN VIEW, Calif. / Feb 11, 2025 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath ® , an innovative, FDA-cleared delivery platform, today announced the closing of its previously announced $12.1 million firm commitment... Read More

MOUNTAIN VIEW, Calif. / Feb 06, 2025 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared delivery platform, today announced the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. All... Read More

MOUNTAIN VIEW, Calif. / Feb 06, 2025 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared delivery platform, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of common stock. All of... Read More

Abstract was presented by TIGeR-PaC Phase III clinical trial Investigator, Paula Novelli, MD, from the University of Pittsburgh Medical Center Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers insight that supports the potential effectiveness of RenovoRx’s TAMP therapy platform in locally advanced pancreatic cancer PK data shows intra-arterial delivery of gemcitabine via TAMP is a targeted treatment option... Read More

RenovoRx Holds a Strong IP Portfolio with 18 Issued Patents and 13 Pending Patents as it Moves Forward with Commercialization and Clinical Trial Plans in 2025 New Patent Filing Anticipated to Expand IP Coverage for RenovoRx’s Innovative TAMP™ Approach to Targeted Drug Delivery MOUNTAIN VIEW, Calif. / Dec 30, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company... Read More

TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appointed Principal Investigator for TIGeR-PaC Study LOS ALTOS, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences... Read More

LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared delivery platform, today announced that it will host an investor fireside chat on... Read More

Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size for RenovoCath of Several Hundred Million Dollars in Annual Sales Global Medical Device Commercial Leader, Richard Stark, Joining RNXT as Commercial... Read More

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical Trial is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer LOS ALTOS, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the... Read More

Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Operations to Achieve Next... Read More

LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing novel targeted oncology therapies based on a local drug-delivery platform, today announced that it is increasing the production of its FDA-cleared RenovoCath catheter-based... Read More

LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the Symposium on Clinical Interventional Oncology (“CIO”) which is being held September 20-22, 2024, at the Loews... Read More

LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will present at H.C. Wainwright’s 26 th Annual Global Investment Conference being held at the Lotte New York Palace Hotel... Read More

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision... Read More

Published data shows that chemotherapy delivered via TAMP™ with prior chemoradiation in Locally Advanced Pancreatic Cancer (LAPC) observed an Overall Survival (OS) of 27-months Targeted chemotherapy delivery via TAMP is currently being evaluated in an ongoing Phase III clinical trial in LAPC LOS ALTOS, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage... Read More

LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced acceptance for publication in an international peer-reviewed journal, The Oncologist. The manuscript is titled, “Treatment of Locally Advanced Pancreatic Cancer... Read More

LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase... Read More

LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt’s appointment highlights... Read More

With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx is well positioned to advance its pivotal Phase III clinical trial, expand development pipeline into additional cancer indications and explore new commercial business development opportunities with its therapeutic technologies LOS ALTOS, Calif. / May 30, 2024 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a... Read More

Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents LOS ALTOS, Calif. / May 21, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a... Read More

LOS ALTOS, Calif. / May 14, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott... Read More

LOS ALTOS, Calif. / May 02, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun R. Bagai, Chief Executive Officer, will present at the Aegis Capital Virtual Conference being held on May 7-9, 2024. Mr. Bagai will discuss recent corporate... Read More

LOS ALTOS, Calif. / Apr 18, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has... Read More

Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers important data to potentially assist in optimization of TAMP therapy LOS ALTOS, Calif. / Apr 16, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical... Read More

With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx has sufficient funding to advance pivotal Phase III clinical trial and expand development pipeline into additional cancer indications LOS ALTOS, Calif. / Apr 15, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on... Read More

Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial Financing also enables the expansion of RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) clinical development pipeline into additional cancer indications LOS ALTOS, Calif. / Apr 08, 2024 / Business... Read More

LOS ALTOS, Calif. / Apr 05, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024.... Read More

LOS ALTOS, Calif. / Mar 12, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA. Mr. Bagai will... Read More

Company has promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer LOS ALTOS, Calif. / Mar 08, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry... Read More

Recent financing will drive Company towards second interim analysis on pivotal Phase III TIGeR-PaC clinical trial by end of 2024 LOS ALTOS, Calif. / Feb 06, 2024 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief... Read More

With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 LOS ALTOS, Calif. / Jan 29, 2024 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today... Read More

This study will be the Second Clinical Trial Evaluating RenovoGem™, a Combination Drug-Device Product, in a Difficult-to-Access Solid Tumor Cancer LOS ALTOS, Calif. / Dec 21, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the expansion of their... Read More

Research Supports RenovoRx’s Lead Oncology Product Candidate, RenovoGem™, and its Novel Therapy Platform, TAMP™, for the Treatment of Locally Advanced Pancreatic Cancer LOS ALTOS, Calif. / Dec 19, 2023 / Business Wire / RenovoRx, Inc . (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical... Read More

RenovoRx Holds a Strong Intellectual Property (IP) Portfolio with 9 Issued Patents for its Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Therapy Platform and Delivery System New Patent Would Expand IP Coverage for TAMP to Deliver Additional Therapeutic Classes Across DNA/RNA Altering Modalities, Cell Therapy, and Antibody-Based Therapies LOS ALTOS, Calif. / Dec 13, 2023 / Business Wire / RenovoRx, Inc. (Nasdaq: RNXT), a... Read More

LOS ALTOS, Calif. / Nov 16, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave... Read More

Collaboration with Imugene further validates TAMP TM (Trans-Arterial Micro-Perfusion) and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy. The TAMP therapy platform is in a Phase III clinical trial for the treatment of Pancreatic Cancer, interim analysis was completed in March 2023, and the Data Monitoring Committee recommended a continuation of the study. TIGeR-PaC is prespecified to... Read More

LOS ALTOS, Calif. / Oct 02, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023. Register here . Moderated by Scott Henry, Managing Director, Senior Research Analyst & Head... Read More

Presented positive Phase III TIGeR-PaC interim study results observing 8-month delay in cancer progression, concordant with 6-month overall survival benefit and 65% reduction in adverse effects over standard of care. Announced collaboration with Imugene to explore delivery of oncolytic virus therapy using proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform, expanding use from targeting locally advanced disease to... Read More

LOS ALTOS, Calif. / Jul 31, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43 rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the... Read More

Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors LOS ALTOS, Calif. & SYDNEY / Jul 20, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted... Read More

Six-Month Overall Survival Benefit with RenovoGem Versus Systemic Chemotherapy, and 65% reduction in adverse effects and clinically meaningful overall survival trend Results highlight RenovoGem’s potential to change treatment paradigm for Locally Advanced Pancreatic Cancer LOS ALTOS, Calif. / Jun 29, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company... Read More

LOS ALTOS, Calif. / Jun 20, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB). “Dr. Tempero has been an international... Read More

Dr. Michael Pishvaian, Principal Investigator of Phase III TIGeR-PaC Clinical Trial, will Discuss Recent Interim Analysis and its Potential Practice-Changing Impact in Oncology LOS ALTOS, Calif. / Jun 12, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that ROTH Capital will host a Key... Read More

Study is Investigating RenovoGem™ as Potential New Option for Pancreatic Cancer Treatment Recent Positive Interim Data Analysis from Study Revealed 60% Survival Benefit and 65% Side Effect Reduction Versus Systemic Chemotherapy LOS ALTOS, Calif. & DALLAS / Jun 01, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination... Read More

Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem™ to Treat Locally Advanced Pancreatic Cancer (LAPC) LOS ALTOS, Calif. / May 25, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination... Read More

LOS ALTOS, Calif. / May 24, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Mr. Bagai will provide a corporate update including recently... Read More

Announced Phase III Interim Study Analysis Results: 60% Survival Benefit and Greater than 65% Reduction in Side Effects with RenovoGem™ Compared to Systemic Chemotherapy in Pancreatic Cancer LOS ALTOS, Calif. / May 15, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial results for the first... Read More

PurpleStride is Raising Awareness of the World’s Toughest Cancer. Fundraising Supports Research, Critical Education, and Support Programs for Patients LOS ALTOS, Calif. / May 01, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced it joined Pancreatic Cancer Action Network (PanCAN) as a sponsor of the... Read More

LOS ALTOS, Calif. / Apr 28, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Shaun Bagai, CEO of RenovoRx, will present at the Aegis Capital Virtual Conference on May 3 rd at 3:30 p.m. ET. The online presentation can be accessed here . The conference will be held May 2-4, 2023. Mr. Bagai will... Read More

LOS ALTOS, Calif. / Apr 27, 2023 / Business Wire / RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced pancreatic cancer (LAPC), announced today that Robert J. Spiegel, MD, has been appointed to the Company’s Board of Directors, effective April 25, 2023. Dr. Spiegel brings more than 40 years of... Read More

Researchers Presenting Interim Data on Poster #CT084 Demonstrating RenovoGem™ Patients May Experience 60% Survival Benefit and 65% Side Effects Reduction Versus Systemic Chemotherapy LOS ALTOS, Calif. / Apr 14, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Poster #CT084 is presenting detailed,... Read More

Ms. Gentry, an Industry Expert in Clinical Trials Management, Adds Valuable Leadership Experience to Advance Studies in Cancer Treatment LOS ALTOS, Calif. / Apr 11, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company as Senior Vice President of Clinical... Read More

LOS ALTOS, Calif. / Mar 30, 2023 / Business Wire / RenovoRx, Inc. (the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,557,632 shares of the Company’s common stock (or common stock equivalents) at a purchase price of... Read More

RenovoGem™ Patients had Greater than 65% Reduction in Side Effects, which can Include Nausea, Fatigue, and Reduced White Blood Cells During Pancreatic Cancer Treatment These Data and Additional Secondary Endpoint Analyses to be Presented at American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023 LOS ALTOS, Calif. / Mar 30, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq:... Read More

In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated. Dr. Pishvaian’s interview with OncologyTube is featured here . Recently RenovoRx (RNXT) announced interim data in the Phase 3 open-label TIGeR-PaC clinical trial investigating the company's first product candidate, RenovoGem, as a potential treatment option in locally... Read More

LOS ALTOS, Calif. / Mar 02, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today is reporting its financial results for the year ended December 31, 2022, and a pipeline update including the status of the interim analysis of for the Company’s Phase III TIGeR-PaC clinical trial . RenovoRx anticipates finalizing... Read More

LOS ALTOS, Calif. / Mar 01, 2023 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announces that Shaun Bagai, Chief Executive Officer, will be presenting at the 35th Annual Roth Conference, to be held March 12-14, 2023, in Dana Point, California. To register for the event, visit the conference website . During... Read More

LOS ALTOS, Calif. / Jan 25, 2023 / Business Wire / RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive Officer, is scheduled to present virtually at the Sequire Biotechnology Conference on Thursday, February 2, 2023 at 4 p.m. (ET). To register for the event, visit the Sequire Biotechnology Conference website . During... Read More

Researchers presenting four abstracts on different substudies, including the preliminary PK substudy, at the ASCO GI Cancers Symposium in San Francisco on January 19-21, 2023. RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokinetic (PK) substudy within the phase III un-blinded randomized control TIGeR-PaC clinical... Read More

Patent broadly covers methods for treating bile duct cancer. RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more... Read More

The accepted abstracts support RenovoRx’s lead oncology product candidate, RenovoGem™, and its novel therapy platform, RenovoTAMP ® , for the treatment of difficult-to-treat cancers. LOS ALTOS, Calif.--( BUSINESS WIRE )-- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts supporting... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP ® ) therapy platform, today announced that the Company’s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27 th at 1 p.m. ET. To register for the event please visit... Read More

RenovoRx, Inc . (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP ® ) therapy platform, today announced management’s participation in two upcoming investor conferences this month. Conferences include ROTH Inaugural Healthcare Opportunities, October 6 th , and LD Micro Main Event XV,... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP TM ) therapy platform, today announced Ripal Gandhi, M.D., FSIR, FSVM presented, “Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer,” at the recent Symposium on Clinical Interventional Oncology (CIO) . Dr. Gandhi... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP TM ) therapy platform, today announced that Angela Gill Nelms has joined the company as Chief Operating Officer (“COO”). “Angela is a growth-oriented operational leader with experience in clinical trial management, a proven... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform, today announced management’s participation in the upcoming H.C. Wainwright 24 th Annual Global Investment Conference. This conference is to be held at the Lotte New York Palace Hotel in New York City on... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP TM ) therapy platform, today reported its financial results for the quarter ended June 30, 2022. “Over the past decade, our team has developed and refined a unique therapy platform for difficult-to-treat solid tumors by... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx. Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to... Read More

RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series – The RenovoRx Story. This video series provides viewers with a unique opportunity to learn more about the Company, its leadership team, and the innovative RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform. Also... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that they will host a webinar highlighting their RenovoTAMP™ therapy platform. The webinar, “Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform,” will be held on Tuesday, June 21 st at 8:00 am (ET). To register for this event,... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will participate in the Gateway to Translation Webinar Series hosted by the University of Cambridge’s Academy of Therapeutic Sciences (CATS) on Wednesday, June 8, 2022 at 1:00 PM ET. Dr. Ramtin Agah, Chief Medical Officer and Co-Founder of RenovoRx, will present a seminar, “Localized Intra-arterial... Read More

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management’s participation in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 in Miami Beach, Florida. H.C. Wainwright Global Investment Conference Format and Dates: Hybrid, May 23-26, 2022 Location: Fountainebleau Miami Beach Hotel, Miami Beach, Florida... Read More

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022. “As we report our Q1 2022 results, we acknowledge that May is Cancer Research Month. RenovoRx is fighting cancer through our innovative localized treatment of difficult-to-treat tumors via our proprietary RenovoTAMP™... Read More

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021. “2021 was a transformative year for RenovoRx. We successfully closed on our initial public offering and listed on the NASDAQ under ‘RNXT,’” said Shaun Bagai, CEO of RenovoRx. “Importantly, despite challenges created by... Read More

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership’s participation in two upcoming Investor Conferences this month. ROTH Capital Partners 34 th Annual Conference Format and Dates: In person, March 13-15, 2022 Location: The Ritz Carlton Laguna Niguel Hotel, Dana Point, CA Presenters and Presentation Date/Time: Shaun... Read More

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center (“Columbia University”), in its ongoing TIGeR-PaC Phase 3 clinical trial. The study is evaluating the Company’s therapy platform... Read More

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the “Delivering Therapy Where it Matters” fireside chat with CEO, Shaun Bagai, on Wednesday, February 23 rd at 12 p.m. ET. During the video webinar, Mr. Bagai will discuss RenovoRx’s unique approach to fighting cancer through localized and targeted chemotherapy. Additionally, he will... Read More

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Dr. Ripal Gandhi, M.D., FSIR, FSVM, a Principal Investigator in the Company’s Phase 3 TIGeR-PaC study, presented ‘Trans-arterial Treatment Option in Pancreas Cancer’ at the recent 2022 SPECTRUM Conference . Dr. Gandhi is professor of Interventional Radiology at the Miami... Read More

RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Shaun Bagai, Chief Executive Officer, will participate in the H.C. Wainwright Bioconnect Virtual Conference on behalf of RenovoRx. The conference will be held January 10-13, 2022. Mr. Bagai’s investor presentation will be available on-demand beginning January 10 th at 7:00 am EST. Management will be... Read More

RenovoRx , Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September 30, 2021. “The third quarter of 2021 marked an important juncture in the growth of our company as we completed our IPO in late August and our seventh U.S. patent was issued for our RenovoTAMP ™ (RenovoRx Trans-Arterial Micro-Perfusion)... Read More

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its novel therapy platform, RenovoTAMP TM (RenovoRx Trans-Arterial Micro-Perfusion), will be highlighted during a presentation by expert panelist, Dr. Ripal Gandhi, at the Miami Cancer Institute’s New Advances in the Management of Pancreatic Cancer CME course this evening. Dr. Gandhi, a Principal Investigator... Read More

RenovoRx , Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System. The RenovoCath Delivery System is the device component of the Company's... Read More